Shionogi Adds to Its Rare Disease Strategy With $2B IntraBio Acquisition
Shionogi’s IntraBio acquisition brings Aqneursa, a drug approved for treating two rare neurological disorders and the potential to expand to additional indications, both rare and common. It’s Shionogi’s second big rare disease move this year, following the acquisition of global rights to an amyotrophic lateral sclerosis drug from Tanabe Pharma.
Trump Administration Announces $90 Payments to Help Cover Medicare Part B Premiums
The Trump administration is issuing one-time $90 payments to more than 20 million Medicare beneficiaries to help cover Part B premiums, though the payments may do little to offset rising healthcare costs.
The Biggest Healthcare Fix Might Not Come From a Vendor
Nobody has ever needed convincing on what to fix. What they've lacked is a way to act on it themselves, in something close to real time instead of on a vendor's roadmap.
presented by
Strengthening Dental Payment Integrity Through Smarter Claim Editing
Fraud, waste, and abuse (FWA) continue to challenge dental plans as overtreatment, miscoding and inappropriate billing practices drive unnecessary costs and weaken payment integrity. For dental payers, the stakes extend beyond financial losses: these issues can also expose members to unnecessary procedures and consume benefits that should be preserved for appropriate care.
Immunology Startup ai3Bio Aims to Redefine What It Means to Reset the Immune System
While the immune reset field is mainly focused on depleting pathogenic B cells, ai3Bio is applying its novel approach to inflammatory T cells. The startup’s initial disease targets are autoimmune disorders of the liver that have few treatment options if any at all.